A national, multi-centre study evaluating Thrombotic Thrombocytopenia Syndrome (TTS) associated with ChAdOx1 (AZD1222) and other SARS-CoV-2 vaccines (viral vector and m-RNA)
- Funded by Medical Research Future Fund (MRFF)
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Known Financial Commitments (USD)
$2,151,643.58Funder
Medical Research Future Fund (MRFF)Principal Investigator
Unspecified Unspecified UnspecifiedResearch Location
AustraliaLead Research Institution
N/AResearch Priority Alignment
N/A
Research Category
Vaccines research, development and implementation
Research Subcategory
Adverse events associated with immunization
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Not applicable
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
A condition of a blood clot with low platelets has been described in some patients after receiving COVID-19 vaccines, including the widely available ChAdOx1 vaccine. Known as thrombosis with thrombocytopenia syndrome (TTS), this condition presents with a wide spectrum of severity. Although it has an immunological basis, the underlying mechanisms is unknown and there are no known predictors for increased risk of TTS. Further understanding is needed to ensure safe COVID-19 vaccination.